NCT06625775 2026-03-18
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1 Recruiting
Clinical Trials
23 trialsNCT04802759 2026-03-16
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT07007559 2026-02-03
ASPEN-09
ALX Oncology Inc.
Phase 1/2 Recruiting
NCT00781612 2025-12-24
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Genentech, Inc.
Phase 2 Active not recruiting
NCT02492711 2025-03-17
SOPHIA
MacroGenics
Phase 3 Completed
NCT04120246 2024-07-10
Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer
Veana Therapeutics
Phase 1 Suspended
NCT01953926 2024-03-12
SUMMIT
Puma Biotechnology, Inc.
Phase 2 Terminated
NCT01969643 2023-03-07
A Safety Study of SGN-LIV1A in Breast Cancer Patients
Seagen Inc.
Phase 1 Completed
NCT00807859 2022-11-08
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Amgen
Phase 1 Completed
NCT04464967 2021-05-12
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
Phase 1/2 Withdrawn
NCT01285466 2020-12-09
A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab
Novartis
Phase 1 Completed
NCT01271920 2020-12-08
Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab
Novartis
Phase 1/2 Completed
NCT00367471 2020-09-09
Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.
Novartis
Phase 1 Completed
NCT00140140 2019-11-26
A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer
Celgene
Phase 1/2 Terminated
NCT03811418 2019-11-26
ATTILA
iOMEDICO AG
Phase 3 Withdrawn
NCT00876395 2018-12-19
BOLERO-1
Novartis
Phase 3 Completed
NCT01512199 2017-10-18
Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)
Daiichi Sankyo
Phase 1/2 Terminated
NCT01774851 2017-06-22
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
Merrimack Pharmaceuticals
Phase 2 Terminated
NCT01304797 2017-01-06
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer
Merrimack Pharmaceuticals
Phase 1 Unknown
NCT00426556 2015-12-28
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
Novartis
Phase 1 Completed
NCT01386580 2015-01-22
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
BBB-Therapeutics B.V.
Phase 1/2 Completed
NCT00031278 2011-05-30
Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer
Pfizer
Phase 1/2 Completed
NCT00171847 2010-03-31
eLEcTRA
Novartis
Phase 4 Terminated